Compare ANNX & FET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | FET |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 873.3M | 850.2M |
| IPO Year | 2020 | 2007 |
| Metric | ANNX | FET |
|---|---|---|
| Price | $4.25 | $81.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 158.1K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.64 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $791,474,000.00 |
| Revenue This Year | N/A | $7.35 |
| Revenue Next Year | $16,320.74 | $6.95 |
| P/E Ratio | ★ N/A | $211.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.54 | $25.07 |
| 52 Week High | $7.18 | $87.42 |
| Indicator | ANNX | FET |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 59.88 |
| Support Level | N/A | $75.68 |
| Resistance Level | $5.63 | $84.16 |
| Average True Range (ATR) | 0.21 | 3.19 |
| MACD | -0.04 | -0.59 |
| Stochastic Oscillator | 37.74 | 66.90 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.